Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity
datasetposted on 02.05.2022, 20:11 authored by Preshendren Govender, Rudolf Müller, Kawaljit Singh, Virsinha Reddy, Charles J. Eyermann, Stephen Fienberg, Sandeep R. Ghorpade, Lizbé Koekemoer, Alissa Myrick, Dirk Schnappinger, Curtis Engelhart, Jaclynn Meshanni, Jo Ann W. Byl, Neil Osheroff, Vinayak Singh, Kelly Chibale, Gregory S. Basarab
New antibiotics with either a novel mode of action or novel mode of inhibition are urgently needed to overcome the threat of drug-resistant tuberculosis (TB). The present study profiles new spiropyrimidinetriones (SPTs), DNA gyrase inhibitors having activity against drug-resistant Mycobacterium tuberculosis (Mtb), the causative agent of TB. While the clinical candidate zoliflodacin has progressed to phase 3 trials for the treatment of gonorrhea, compounds herein demonstrated higher inhibitory potency against Mtb DNA gyrase (e.g., compound 42 with IC50 = 2.0) and lower Mtb minimum inhibitor concentrations (0.49 μM for 42). Notably, 42 and analogues showed selective Mtb activity relative to representative Gram-positive and Gram-negative bacteria. DNA gyrase inhibition was shown to involve stabilization of double-cleaved DNA, while on-target activity was supported by hypersensitivity against a gyrA hypomorph. Finally, a docking model for SPTs with Mtb DNA gyrase was developed, and a structural hypothesis was built for structure–activity relationship expansion.
Read the peer-reviewed publication
phase 3 trialsminimum inhibitor concentrationsg ., compoundclinical candidate zoliflodacinanalogues showed selective50 </ sub42 </ bdna gyrase inhibitiondna gyrasemtb </cleaved dnaurgently neededstructural hypothesisresistant tuberculosisnovel modenegative bacteriainvolve stabilizationgyra hypomorphdocking modelcausative agent49 μm